Zhaoke Ophthalmology Limited (6622.HK)

HKD 1.32

(0.0%)

EBITDA Summary of Zhaoke Ophthalmology Limited

Zhaoke Ophthalmology Limited's latest annual EBITDA in 2023 was -327.86 Million CNY , up 11.14% from previous year.
Zhaoke Ophthalmology Limited's latest quarterly EBITDA in 2024 Q2 was -42.11 Million CNY , down 0.0% from previous quarter.
Zhaoke Ophthalmology Limited reported an annual EBITDA of -369.1 Million CNY in 2022, up 82.42% from previous year.
Zhaoke Ophthalmology Limited reported an annual EBITDA of -377.52 Million CNY in 2021, down -197.6% from previous year.
Zhaoke Ophthalmology Limited reported a quarterly EBITDA of -42.11 Million CNY for 2024 Q1, up 53.23% from previous quarter.
Zhaoke Ophthalmology Limited reported a quarterly EBITDA of -90.03 Million CNY for 2023 Q3, up 24.95% from previous quarter.

Annual EBITDA Chart of Zhaoke Ophthalmology Limited (2023 - 2018)

Historical Annual EBITDA of Zhaoke Ophthalmology Limited (2023 - 2018)

Year	EBITDA	EBITDA Growth
2023	-327.86 Million CNY	11.14%
2022	-369.1 Million CNY	82.42%
2021	-377.52 Million CNY	-197.6%
2020	-100.7 Million CNY	-578.83%
2019	-86.47 Million CNY	-259.48%
2018	-28.91 Million CNY	0.0%

Year	EBITDA	EBITDA Growth
2024 Q2	-42.11 Million CNY	0.0%
2024 Q1	-42.11 Million CNY	53.23%
2023 Q3	-90.03 Million CNY	24.95%
2023 FY	- CNY	11.14%
2023 Q4	-90.03 Million CNY	0.0%
2023 Q2	-119.97 Million CNY	0.0%
2023 Q1	-119.97 Million CNY	1.91%
2022 Q3	-122.31 Million CNY	-74.84%
2022 Q2	-69.95 Million CNY	0.0%
2022 Q1	-69.95 Million CNY	10.53%
2022 FY	- CNY	82.42%
2022 Q4	-122.31 Million CNY	0.0%
2021 Q1	-110.56 Million CNY	-119.87%
2021 Q2	-110.56 Million CNY	0.0%
2021 Q4	-78.19 Million CNY	0.0%
2021 Q3	-78.19 Million CNY	29.28%
2021 FY	- CNY	-197.6%
2020 Q4	-50.28 Million CNY	0.0%
2020 Q1	-18.46 Million CNY	-3.93%
2020 Q2	-18.46 Million CNY	0.0%
2020 FY	- CNY	-578.83%
2019 FY	- CNY	-259.48%
2019 Q4	-17.76 Million CNY	0.0%
2018 FY	- CNY	0.0%

Peer EBITDA Comparison of Zhaoke Ophthalmology Limited

Name	EBITDA	EBITDA Difference
Uni-Bio Science Group Limited	91.23 Million HKD	459.365%
CK Life Sciences Int'l., (Holdings) Inc.	486.79 Million HKD	167.351%